CK19、Ki67、CK7在肝细胞癌组织中的表达

肝脏 ›› 2022, Vol. 27 ›› Issue (8): 887-890.

CK19、Ki67、CK7在肝细胞癌组织中的表达

周锦宏, 崇杨

215300 江苏泰州市第二人民医院普外科(周锦宏);扬州大学附属医院普外科(崇杨)

收稿日期:2021-10-11 出版日期:2022-08-31 发布日期:2022-09-30
通讯作者: 崇杨
基金资助:
江苏省自然科学基金资助项目(SBK201822212)

The expressions of CK19, Ki67 and CK7 in hepatocellular carcinoma tissues

ZHOU Jin-hong¹, CHONG Yang²

1. Department of General Surgery,Taizhou Second People's Hospital, Jiangsu 215300, China;
2. Department of General Surgery,Affiliated Hospital of Yangzhou University, Jiangsu 225001, China

Received:2021-10-11 Online:2022-08-31 Published:2022-09-30
Contact: CHONG Yang

摘要/Abstract

摘要： 目的观察细胞角蛋白19(CK19)、增殖细胞核抗原(Ki67)、细胞角蛋白7(CK7)在肝细胞癌(HCC)组织中的表达情况。方法以泰州市第二人民医院2016年3月至2018年3月65例HCC患者作为研究对象。取患者手术后癌组织与癌旁正常组织,采用免疫组织化学测定CK19、Ki67、CK7表达情况,比较癌组织和癌旁组织中CK19、Ki67、CK7阳性检出率。对比不同临床病理特征HCC患者癌组织中CK19、Ki67、CK7阳性检出率,观察CK19、Ki67、CK7不同表达HCC患者的3年生存情况。结果癌组织中CK19、Ki67、CK7阳性检出率分别为40.00%(26/65)、73.85%(48/65)、70.77%(46/65),均高于癌旁组织的1.54%(1/65)、23.08%(15/65)、1.54%(1/65),差异有统计学意义(χ²=29.216、33.639、67.483,P<0.05)。TNM分期为Ⅲ~Ⅳ期、组织低分化、淋巴结转移、有被膜浸润患者的CK19、Ki67、CK7阳性检出率较高(P<0.05),CK19、Ki67、CK7阳性HCC患者3年生存率分别为34.52%(9/26)、58.33%(28/48)、58.70%(27/46),低于CK19、Ki67、CK7阴性患者3年生存率87.18%(34/39)、88.24%(15/17)、84.21%(16/19),差异有统计学意义(χ²=19.250、4.767、3.910,P<0.05)。结论 HCC患者癌组织中CK19、Ki67、CK7呈高表达,其表达水平与TNM分期、组织分化程度、淋巴结转移、被膜浸润密切相关。

关键词: 细胞角蛋白19, 增殖细胞核抗原, 细胞角蛋白7, 原发性肝细胞癌

Abstract: Objective To observe the expression of cytokeratin 19 (CK19), proliferating cell nuclear antigen (Ki67) and cytokeratin 7 (CK7) in primary hepatocellular carcinoma (HCC) tissues.Methods 65 patients with HCC hospitalized from March 2016 to March 2018 were selected as the research objects. The specimens of cancer tissue and adjacent normal tissue were taken during operation. The expressions of CK19, Ki67 and CK7 were measured by immunohistochemical staining. The positive rates of CK19, Ki67 and CK7 between cancer tissues and adjacent tissues were compared. The positive detection rates of CK19, Ki67 and CK7 in cancer tissues of HCC patients with different clinicopathological features were counted and compared. The 3-year survival of HCC patients with different expression levels of CK19, Ki67 and CK7 were analyzed.Results The positive rates of CK19, Ki67 and CK7 in cancer tissues were 40.00%, 73.85% and 70.77% respectively, which were significantly higher than those of 1.54%, 23.08% and 1.54% in adjacent tissues (χ²=29.216, 33.639, 67.483; P<0.05). The positive rates of CK19, Ki67 and CK7 were higher in HCC patients with TNM stage III~IV, poorly differentiated tissue, lymph node metastasis and capsule infiltration (P<0.05). The positive rates of CK7, CK19 and Ki67 in patients with lymph node metastasis and capsule infiltration were higher (P<0.05). The 3-year survival rates of CK19, Ki67 and CK7 positive HCC patients were 34.52%, 58.33% and 58.70% respectively, which were lower than those of 87.18%, 88.24% and 84.21% in negative HCC patients (Log-rank=19.250, 4.767, 3.910; P<0.05).Conclusion The expression levels of CK19, Ki67 and CK7 were highly correlated with TNM stage, tissue differentiation, lymph node metastasis and capsule infiltration, and have impact on the survival of HCC patients.

Key words: Cytokeratin 19, Proliferating cell nuclear antigen, Cytokeratin 7, Primary hepatocellular carcinoma

周锦宏, 崇杨. CK19、Ki67、CK7在肝细胞癌组织中的表达[J]. 肝脏, 2022, 27(8): 887-890.

ZHOU Jin-hong, CHONG Yang. The expressions of CK19, Ki67 and CK7 in hepatocellular carcinoma tissues[J]. Chinese Hepatolgy, 2022, 27(8): 887-890.

参考文献

[1] Erhamamci S, Aslan N. Primary hepatocellular carcinoma with intense 68Ga-PSMA uptake but slight 18F-FDG uptake on PET/CT imaging. Clin Nucl Med, 2020, 45(3):1-1.
[2] Lee C, Lin S, Tsai H, et al. Cadherin 17 is related to recurrence and poor prognosis of cytokeratin 19positive hepatocellular carcinoma. Oncol Lett, 2018,15(1):559-567.
[3] Lai YS, Cheng CC, Lee MT, et al. The prognostic value of cytokeratin and sal-like protein 4 expression in hepatocellular carcinoma and intra-hepatic cholangiocarcinoma in Taiwan. Int J Med Sci, 2018, 15(14):1746.
[4] 贾磊, 李豪, 白鸿太,等. CD34和Ki67的表达预测肝癌术后复发的风险. 肝脏, 2020, 25(2):100-102.
[5] Stephen B, Edge, Carolyn C,Compton.The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol,2010,17(6):1471-1474.
[6] 中华人民共和国卫生部. 原发性肝癌诊疗规范(2011年版). 临床肝胆病杂志,2011, 20(11):929-946.
[7] 安晓刚, 马万龙, 马玉,等. 血清细胞角蛋白19检测在原发性肝癌中的应用价值. 宁夏医科大学学报, 2018, 40(2):211-213.
[8] Lorente L. New prognostic biomarkers of mortality in patients undergoing liver transplantation for hepatocellular carcinoma. World J Gastroenterol, 2018,24(37):4230-4242.
[9] 李镇利, 吴寒, 杨田,等. 基于肝细胞癌微环境和生物标志物特点构建靶向性纳米载体的研究与应用. 肝胆胰外科杂志, 2019, 31(3):58-62.
[10] Garg R, Srinivasan R, Dey P, et al. Utility of cytokeratin7 immunocytochemistry in the cytopathological diagnosis of fibrolamellar hepatocellular carcinoma. J Cytol, 2018, 35(2):75-78.
[11] Choi SY, Kim SH, Park CK, et al. Imaging features of gadoxetic acid-enhanced and diffusion-weighted MR imaging for identifying cytokeratin 19-positive hepatocellular carcinoma: a retrospective observational study. Radiology, 2018, 286(3):897-908.
[12] Akita M, Ajiki T, Fukumoto T, et al. Keratin 19-expressing hepatocellular carcinoma and small‐duct type intrahepatic cholangiocarcinoma show a similar postoperative clinical course but have distinct genetic features. Histopathology, 2019,75(3):385-393.
[13] 邹柯涵, 徐敏, 罗书笛,等. CK,Ki67,Gly-3及P53在肝细胞癌组织中的表达. 湖南中医药大学学报, 2017, 37(3):326-328.
[14] 杨晓珍, 龙江, 赵鹏,等. 肝癌分化程度与肝脏CT强化特点及CD34,p53,GPC3,CK19,Ki-67表达的关系. 癌症进展, 2018, 16(15):1892-1895.
[15] 邓冲, 郭德良, 谢雄伟. SEPT9基因在人肝细胞癌侵袭转移中的作用. 肝脏, 2019, 24(8):910-914.
[16] 魏复群, 罗柳平, 梁东,等. Ki-67表达与原发性肝癌根治性切除术后行预防性肝动脉化疗栓塞患者预后的关系. 中国普通外科杂志,2019,28(7):825-832.